Aribio has secured a strategic investment of approximately 42.5 billion won (about $27 million) from China's Puxing Pharmaceutical, accelerating the global commercialization of its Alzheimer's treatment, AR1001. This investment follows a large-scale technology export contract, further solidifying the partnership between the two companies.
On July 5, Aribio announced it had signed a strategic equity investment agreement with Puxing Pharmaceutical worth a total of $27.5 million (approximately 42.5 billion won). Puxing will initially invest $7.5 million (about 11.5 billion won) and has the option to invest an additional $20 million (around 31 billion won) later. Upon completion of the second investment, Puxing will become Aribio's third-largest shareholder, following Sorux (soon to be renamed Aribio Holdings) and Samjin Pharmaceutical.
This investment is seen as a continuation of the approximately $53.8 billion (about 7 trillion won) global exclusive development and commercialization agreement for AR1001 that the two companies signed in May, with Puxing securing global rights outside of Korea and China.
Industry experts note that it is rare for a strategic equity investment to follow a large-scale technology export in such a short time, reflecting high confidence in the commercial potential of the candidate drug.
AR1001 is a low-molecular-weight drug candidate being developed as the world's first oral disease-modifying treatment (DMT) for Alzheimer's disease. Unlike existing antibody therapies, it offers greater convenience in administration and targets the complex pathology of the disease through multiple mechanisms, including improving cerebral blood flow, protecting nerve cells, reducing brain inflammation, and inhibiting tau protein hyperphosphorylation.
Aribio recently completed patient dosing in its global Phase 3 clinical trial (POLARIS-AD). The trial, which began in December 2022 in the United States, involved over 230 institutions across 13 countries, including Korea, the U.S., Canada, Europe, and China, with 1,535 early Alzheimer's patients registered. Of these, 1,348 completed the 52-week main trial dosing.
Notably, despite the long duration of the trial, the dropout rate was only 12.2%, and 95.5% of the completed patients chose to participate in the extension study. The company interprets this as a positive signal regarding patient adherence and drug safety. The extension study is expected to conclude in June 2027.
Aribio is currently conducting data cleaning and statistical analysis and plans to announce topline results containing key indicators between September and October. The data obtained will serve as crucial evidence for global regulatory strategies and the expansion of additional partnerships.
On the commercialization front, Aribio has secured global licensing agreements worth a total of 10 trillion won for AR1001 for a single indication. This includes rights for North America, Europe, and Japan, in addition to agreements with Samjin Pharmaceutical (Korea), Arsera (UAE, Middle East, and South America), and Puxing Pharmaceutical (Greater China and ASEAN).
An Aribio representative stated, "This strategic investment is a recognition of AR1001's technological capabilities and growth potential. We will successfully drive global commercialization and continue to expand our innovative drug development collaborations."
Meanwhile, the number of dementia patients is rising, leading to increased social costs. According to the Central Dementia Center under the Ministry of Health and Welfare, the estimated number of dementia patients aged 65 and older in Korea this year is 984,601, with a prevalence rate of 10.41%. The socioeconomic costs associated with dementia management are estimated to reach 22.6468 trillion won annually.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.